PARADISE MI Trial: sacubitril/valsartan effective for heart attack

The  PARADISE -MI trial assesed the efficacy and safety of sacubitril/valsartan compared with ramipril in a contemporary acute myocardial infarction population.  Heart attack is an extremely dangerous condition with significant mortality rate. The lack of blood flow can occur because of many different factors but is usually related to a blockage in one or more of arteries. 

A total of 2,830 in sacubitril/valsartan (target dose 97/103 mg twice a day) or 2,831 ramipril (target 5 mg twice a day) were grouped. The primary outcome of cardiovascular (CV) death, first Heart Failure hospitalization, or outpatient Heart Failure for sacubitril/valsartan vs. ramipril, was: 11.9% vs. 13.2%.

The results of this trial in American College of Cardiology indicates that the combination sacubitril/valsartan did not reduce the primary endpoint in a contemporary enriched acute myocardial infarction population, compared with ramipril. These are interesting findings and add to the available data with angiotensin receptor-neprilysin inhibitors.